A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature

Cancer Cell. 2017 Apr 10;31(4):469-471. doi: 10.1016/j.ccell.2017.03.009.


In this issue of Cancer Cell, Seaman et al. demonstrate that antibody drug conjugates (ADCs) against CD276 expressed by tumor cells and tumor vasculature have promising anti-tumor activity while showing little toxicity. Importantly, these agents have the potential to target both angiogenic vessels and non-angiogenic vessels co-opted by tumor cells.

Publication types

  • Comment

MeSH terms

  • Antibodies*
  • Cell Line, Tumor*
  • Humans
  • Immunoconjugates


  • Antibodies
  • Immunoconjugates